Abviris Home

Tumor marker

A blood based entire body screen to find HPV induced cancer early - all within minutes and by using just one drop of blood

Prevo-Check®

Rapid test for detecting HPV16 induced carcinomas early. Easy to use in doctor's practice.
Clinical specificity > 99%

White Papers

Learn more about screening for HPV induced cancer in the white paper series "Guidelines for identifying high-risk patients"

Online Courses

Interactive training resources on early detection of HPV-induced carcinomas

previous arrow
next arrow
Slider

Moving from cell to blood based HPV cancer screening.

Abviris offers a new patented generation of Immune Oncology Diagnostics for early detection of HPV induced cancer, allowing a blood based entire body screen within minutes just using one drop of blood.

Learn more about Prevo-Check®

News

Study involving Prevo-Check® is shortlisted for an award by the UK Diagnostics Summit 2019

A study investigating the use of Prevo-Check® for the early detection of HPV16-induced anal cancer has been shortlisted for a UK Diagnostics Award in the category “Pilot of the Year”. Conducted by the German Competence Network for HIV/AIDS, the retrospective study showed that Prevo-Check® would have helped achieving an anal cancer diagnosis up to 9.5 …

New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1 for early detection of HPV-induced diseases

Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7. In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying …

Investors Convinced of Potential and Importance of a Novel Cancer Management Concept

Abviris GmbH Obtains Almost 3 Million Euros in Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that …

Events